What Is Ultherapy? MFU-V Technology Explained

Ultherapy® (MFU-V) delivers focused ultrasound energy at three preset depths — 1.5 mm (superficial dermis), 3.0 mm (mid dermis), 4.5 mm (SMAS) — creating thermal coagulation points that trigger new collagen and elastin formation over 2–3 months. Real-time B-mode visualization distinguishes MFU-V from generic HIFU. FDA-cleared: 2009 brow lift, 2012 submental and lateral neck laxity, 2014 décolletage wrinkles. Performed only by trained clinicians; not a surgical alternative for advanced laxity.

Ultherapy® is a brand name for microfocused ultrasound with visualization, abbreviated MFU-V. The device sends acoustic energy from a handheld transducer into the skin and produces small, well-defined zones of thermal injury at controlled depths^[1]. Those zones have two effects. The treated tissue contracts straight away, which gives a modest immediate tightening. Then a slower wound-healing response sets in, generating new collagen and, as more recent histology shows, new elastin over the following two to three months^[2].

For patients comparing devices, the question that matters is rarely whether ultrasound is more powerful than radiofrequency or laser. It is what MFU-V actually delivers, and on which patients. This page stays on the technology and the FDA status. Candidacy has its own page, and so does the comparison with generic HIFU.

How the energy is delivered

An MFU-V handpiece carries interchangeable transducers, each tuned to a particular depth. The Ultherapy system as marketed in dermatology practices uses three standard depths — 1.5 mm, 3.0 mm, and 4.5 mm — though not every patient is treated at every depth. Histological work on in vivo skin samples confirms that elongated thermal coagulation points appear at exactly these three focal depths after treatment^[2]. The dermatologist selects depths based on the zone being treated: 1.5 mm transducers address fine etched lines in the décolletage, 3.0 mm targets the dermal collagen network across the cheek, and 4.5 mm reaches the superficial musculoaponeurotic system (SMAS) — the connective tissue layer that surgeons mobilise during a facelift^[3].

Each pulse, called a line, deposits energy at the chosen focal depth. The visualization screen on the device shows the actual tissue along the transducer's path before the line is fired, which lets the clinician avoid bone, large vessels, and previously treated planes. This is the "V" in MFU-V and the single most important feature distinguishing it from generic HIFU devices that fire blind.

FDA clearances — what they actually cover

It is common to read marketing copy that lists Ultherapy as "FDA approved" for everything from jowls to wrinkles. The accurate picture is narrower. The device holds three clearances:

• 2009 — clearance for non-invasive brow lift.
• 2012 — clearance for the appearance of lax submental tissue and lateral neck skin.
• 2014 — clearance for improvement of lines and wrinkles on the décolletage.

Anything beyond those three indications — full-face lifting, jawline definition, peri-oral lines — is technically off-label, even if it is widely and reasonably practised. Off-label use is not the same as unproven use; many devices in dermatology have a narrow regulatory label and a broader evidence-supported clinical envelope. But it does mean patients should be cautious of clinics that advertise "FDA-approved jawline lifting" or similar precision claims.

What happens in the dermis after treatment

The thermal coagulation zones created by MFU-V are small, discrete, and surrounded by intact tissue. That is by design: the intact tissue between zones supports normal healing and serves as a scaffold for the remodelling that follows. HSP47-positive fibroblasts are recruited to the coagulation sites, and by day 90 mature collagen — and newly synthesised elastin — is present in the treated zones^[2]. By two to three months, the remodelled matrix is organised and the visible result — a mild lift, tightening of skin texture, and sometimes a small change to jawline definition — is at its peak.

Patients should not expect to see the final result immediately. The day-of-treatment effect, beyond mild redness and a sense of warmth, is usually subtle. The change that matters builds quietly and is most apparent in photographs taken in consistent lighting around the twelve-week mark.

How long the result lasts

For most patients the visible improvement lasts twelve to eighteen months. Retrospective evaluation at 180 days post-treatment found that 67% of subjects showed blinded-reviewer improvement and 77.7% showed physician-rated improvement after a single MFU-V session, with no association between outcome and Fitzpatrick skin type or age^[4]. A subset, particularly patients with good baseline skin quality, consistent sun protection, and no major weight fluctuations, see results lasting longer. Ultherapy is not a permanent treatment — no non-surgical collagen-induction modality is — and the underlying ageing process continues. Maintenance is a personal decision, often revisited every twelve to twenty-four months.

What MFU-V is not for

MFU-V is a tightening and lift technology operating in the deep dermis and SMAS. It does not treat surface concerns: pigmentation, fine surface telangiectasia, acne scarring, or wrinkles that originate in muscle movement. Those concerns have better-matched tools: pigmented laser, vascular laser, fractional resurfacing, neuromodulators. A careful dermatologist combines or sequences modalities. An Ultherapy session on its own is rarely the complete answer for someone with several skin concerns.

For the broader procedure menu and combination protocols available at the parent clinic, you can see the main Delight Dermatology site for the full procedure menu. Combination planning is one of the things best handled in person, but knowing the available tools beforehand makes the consultation more productive.

Pain and anesthesia

The honest answer is that MFU-V is uncomfortable, particularly at the 4.5 mm depth over bony zones (the jawline, the lower chin). Most clinics offer one or more of: oral analgesia taken before the session, topical anesthetic applied for thirty to sixty minutes, and a short course of an anxiolytic for highly sensitive patients. Local nerve blocks are also used by some clinicians. The clinical team should discuss the option mix with you at consultation; tolerance varies more than most people expect.

Risks and contraindications

Ultherapy® (MFU-V) is well tolerated when performed by a trained dermatologist, but it is not risk-free. Common transient effects include redness and warmth (resolves in hours), mild swelling at 1–3 days, and occasional bruising at the jawline. Rare adverse events include temporary numbness in a specific facial zone, transient weakness of a facial muscle, small areas of skin sensitivity, and — in patients with permanent dermal filler in the focal path — focal nodules or fat atrophy. In a 52-patient open-label trial across Fitzpatrick III–VI skin, the three reported adverse events resolved by day 90 without sequelae^[5].

Absolute contraindications: pregnancy and breastfeeding, active infection in the treatment area, open wounds or recent surgical incisions in the zone, and significant immunosuppression. Relative contraindications discussed at consultation: keloid history, autoimmune skin disease, recent dermal fillers, and clinically indicated anticoagulation that cannot be safely paused.

The next page — MFU-V vs HIFU — covers the most common point of patient confusion: why two devices that both use focused ultrasound deliver such different clinical experiences.

Medically reviewed by a Korean Board-Certified Dermatologist (AAD International Fellow · ASLMS member). Last reviewed 2026-06-08.